Home LiteratureArticle Details
PMID: 19536109 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Genetic prognostic and predictive markers in colorectal cancer.

Nature reviews. Cancer ·Vol. 9 ·No. 7 ·2009-07-00 ·Pages 489-99

Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D

Abstract

Despite many studies of the likely survival outcome of individual patients with colorectal cancer, our knowledge of this subject remains poor. Until recently, we had virtually no understanding of individual responses to therapy, but the discovery of the KRAS mutation as a marker of probable failure of epidermal growth factor receptor (EGFR)-targeted therapy is a first step in the tailoring of treatment to the individual. With the application of molecular analyses, as well as the ability to perform high-throughput screens, there has been an explosive increase in the number of markers thought to be associated with prognosis and treatment outcome in this disease. In this Review, we attempt to summarize the sometimes confusing findings, and critically assess those markers already in the public domain.

MeSH Terms
Biomarkers, Tumor Camptothecin/analogs & derivatives,therapeutic use Capecitabine Chromosomes, Human, Pair 18 Colorectal Neoplasms/drug therapy,genetics,mortality Deoxycytidine/analogs & derivatives,therapeutic use Fluorouracil/analogs & derivatives,therapeutic use Gene Expression Profiling Genes, APC Genes, p53 Genomic Instability Humans Irinotecan Microsatellite Instability Mutation Organoplatinum Compounds/therapeutic use Oxaliplatin Pharmacogenetics Prognosis Proto-Oncogene Proteins/genetics Proto-Oncogene Proteins B-raf/genetics Proto-Oncogene Proteins p21(ras) beta Catenin/metabolism ras Proteins/genetics
Chemicals
Biomarkers, Tumor KRAS protein, human Organoplatinum Compounds Proto-Oncogene Proteins beta Catenin Oxaliplatin Deoxycytidine Capecitabine Irinotecan BRAF protein, human Proto-Oncogene Proteins B-raf Proto-Oncogene Proteins p21(ras) ras Proteins Fluorouracil Camptothecin
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Walther Axel
Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK.
Johnstone Elaine
Swanton Charles
Midgley Rachel
Tomlinson Ian
Kerr David
References (141)
141 references, click to expand
  1. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.
    Br J Cancer. 2001 Sep 1;85(5):692-6 PMID: 11531254
  2. Challenges in projecting clustering results across gene expression-profiling datasets.
    J Natl Cancer Inst. 2007 Nov 21;99(22):1715-23 PMID: 18000217
  3. Frameshift mutator mutations.
    Nature. 1996 Aug 8;382(6591):499-500 PMID: 8700220
  4. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy.
    Clin Cancer Res. 2006 May 15;12(10):3050-6 PMID: 16707601
  5. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.
    J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 PMID: 12509396
  6. Microarrays and molecular research: noise discovery?
    Lancet. 2005 Feb 5-11;365(9458):454-5 PMID: 15705441
  7. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer.
    Pharmacogenet Genomics. 2008 Feb;18(2):161-8 PMID: 18192902
  8. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.
    Cancer Res. 1998 Nov 15;58(22):5248-57 PMID: 9823339
  9. Targeting RAS signalling pathways in cancer therapy.
    Nat Rev Cancer. 2003 Jan;3(1):11-22 PMID: 12509763
  10. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
    Cancer Res. 2003 Sep 15;63(18):5738-44 PMID: 14522894
  11. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.
    Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5 PMID: 9618505
  12. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels.
    Pharmacogenetics. 2004 May;14(5):319-27 PMID: 15115918
  13. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
    J Clin Oncol. 2006 Nov 20;24(33):5313-27 PMID: 17060676
  14. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count.
    Am J Med. 1983 May;74(5):786-94 PMID: 6837602
  15. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.
    J Clin Oncol. 2004 Feb 1;22(3):529-36 PMID: 14752076
  16. Evolution of nonsurgical therapy for colorectal cancer.
    Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):108-20 PMID: 19153564
  17. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    J Clin Oncol. 2008 Dec 10;26(35):5705-12 PMID: 19001320
  18. Colorectal cancer and genetic alterations in the Wnt pathway.
    Oncogene. 2006 Dec 4;25(57):7531-7 PMID: 17143297
  19. Systematic review of microsatellite instability and colorectal cancer prognosis.
    J Clin Oncol. 2005 Jan 20;23(3):609-18 PMID: 15659508
  20. Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis.
    Clin Breast Cancer. 2006 Dec;7(5):372-9 PMID: 17239261
  21. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.
    Cancer Res. 2005 Jul 15;65(14):6063-9 PMID: 16024606
  22. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.
    Int J Oncol. 2001 Aug;19(2):383-6 PMID: 11445856
  23. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer.
    Cancer Res. 1995 Dec 1;55(23):5548-50 PMID: 7585632
  24. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    N Engl J Med. 2008 Oct 23;359(17):1757-65 PMID: 18946061
  25. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Pharmacogenomics J. 2002;2(1):43-7 PMID: 11990381
  26. Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways.
    J Clin Pathol. 1999 Jun;52(6):455-60 PMID: 10562815
  27. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity.
    Cancer Res. 2003 Jun 1;63(11):2898-904 PMID: 12782596
  28. Gene-expression signatures in breast cancer.
    N Engl J Med. 2003 Apr 24;348(17):1715-7; author reply 1715-7 PMID: 12712998
  29. Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas.
    Cancer Res. 2007 Jan 1;67(1):41-56 PMID: 17210682
  30. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression.
    Clin Cancer Res. 2001 Dec;7(12):4096-101 PMID: 11751507
  31. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.
    Science. 1997 Feb 14;275(5302):967-9 PMID: 9020077
  32. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
    Gut. 2009 Jan;58(1):90-6 PMID: 18832519
  33. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Pharmacogenet Genomics. 2005 Oct;15(10):723-30 PMID: 16141798
  34. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    Eur J Cancer. 2004 May;40(7):939-50 PMID: 15093568
  35. Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer.
    Oncology. 2003;64(3):259-65 PMID: 12697967
  36. Gene expression profiling predicts clinical outcome of breast cancer.
    Nature. 2002 Jan 31;415(6871):530-6 PMID: 11823860
  37. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability.
    Cancer Res. 2005 Dec 15;65(24):11361-6 PMID: 16357143
  38. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients.
    Gastroenterology. 2006 Sep;131(3):729-37 PMID: 16952542
  39. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    J Clin Oncol. 2005 Sep 1;23(25):5900-9 PMID: 16043828
  40. False discovery rate, sensitivity and sample size for microarray studies.
    Bioinformatics. 2005 Jul 1;21(13):3017-24 PMID: 15840707
  41. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
    J Clin Oncol. 2008 Apr 1;26(10):1626-34 PMID: 18316791
  42. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines.
    Br J Cancer. 2008 Nov 18;99(10):1607-12 PMID: 18941461
  43. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer.
    Clin Cancer Res. 2008 Oct 1;14(19):6005-13 PMID: 18829479
  44. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
    Clin Cancer Res. 2008 Feb 1;14(3):817-25 PMID: 18245544
  45. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis.
    Gut. 2008 Jul;57(7):941-50 PMID: 18364437
  46. APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status.
    Scand J Gastroenterol. 2002 Oct;37(10):1184-93 PMID: 12408524
  47. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis.
    Eur J Cancer. 2005 Sep;41(14):2060-70 PMID: 16125380
  48. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer.
    Gastroenterology. 1998 Jun;114(6):1188-95 PMID: 9609755
  49. Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.
    Oncogene. 2007 Apr 19;26(18):2642-8 PMID: 17043639
  50. P53 abnormalities and outcomes in colorectal cancer: a systematic review.
    Br J Cancer. 2005 Feb 14;92(3):434-44 PMID: 15668707
  51. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer.
    Mol Cancer. 2007 Aug 23;6:54 PMID: 17716371
  52. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.
    Pharmacogenetics. 2004 Dec;14(12):785-92 PMID: 15608557
  53. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.
    J Clin Oncol. 2007 Mar 1;25(7):767-72 PMID: 17228023
  54. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer.
    Gastroenterology. 2005 Sep;129(3):837-45 PMID: 16143123
  55. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.
    J Clin Oncol. 2005 Mar 1;23(7):1365-9 PMID: 15735113
  56. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    J Clin Oncol. 2005 Oct 20;23(30):7518-28 PMID: 16172461
  57. Cancer-susceptibility genes. Gatekeepers and caretakers.
    Nature. 1997 Apr 24;386(6627):761, 763 PMID: 9126728
  58. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability.
    Neoplasia. 2005 Feb;7(2):99-108 PMID: 15802015
  59. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
    J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5 PMID: 17728214
  60. The cellular pharmacology of oxaliplatin resistance.
    Eur J Cancer. 2002 Jul;38(10):1405-12 PMID: 12091073
  61. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience.
    Cancer. 1986 May 1;57(9):1866-70 PMID: 3485470
  62. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
    J Clin Invest. 1996 Aug 1;98(3):610-5 PMID: 8698850
  63. Classification of Dukes' B and C colorectal cancers using expression arrays.
    J Cancer Res Clin Oncol. 2003 May;129(5):263-71 PMID: 12750996
  64. Genomic instability occurs in colorectal carcinomas but not in adenomas.
    Hum Mutat. 1993;2(5):351-4 PMID: 8257987
  65. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting.
    J Natl Cancer Inst. 2007 Jan 17;99(2):147-57 PMID: 17227998
  66. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24.
    Nat Genet. 2007 May;39(5):645-9 PMID: 17401363
  67. Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer.
    J Mol Diagn. 2008 Jul;10(4):346-54 PMID: 18556775
  68. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    J Clin Oncol. 2009 Apr 10;27(11):1814-21 PMID: 19273709
  69. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients.
    Oncol Rep. 2007 May;17(5):1089-94 PMID: 17390049
  70. Prediction of cancer outcome with microarrays: a multiple random validation strategy.
    Lancet. 2005 Feb 5-11;365(9458):488-92 PMID: 15705458
  71. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.
    Cancer Cell. 2007 Jun;11(6):498-512 PMID: 17560332
  72. Pharmacogenomics in colorectal cancer.
    Semin Oncol. 2003 Aug;30(4 Suppl 15):47-53 PMID: 14523795
  73. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer.
    Nat Genet. 2007 Jul;39(7):870-4 PMID: 17529973
  74. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet. 2007 Dec 15;370(9604):2020-9 PMID: 18083404
  75. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
    Clin Cancer Res. 2005 Sep 1;11(17):6311-6 PMID: 16144935
  76. Inactivation of hCDC4 can cause chromosomal instability.
    Nature. 2004 Mar 4;428(6978):77-81 PMID: 14999283
  77. Chemotherapeutic implications in microsatellite unstable colorectal cancer.
    Cancer Biomark. 2006;2(1-2):51-60 PMID: 17192059
  78. Epidermal growth factor-related peptides and their receptors in human malignancies.
    Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 PMID: 7612182
  79. Stage II colon cancer prognosis prediction by tumor gene expression profiling.
    J Clin Oncol. 2006 Oct 10;24(29):4685-91 PMID: 16966692
  80. A common variant on chromosome 9p21 affects the risk of myocardial infarction.
    Science. 2007 Jun 8;316(5830):1491-3 PMID: 17478679
  81. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer.
    Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5923-8 PMID: 16585533
  82. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis.
    Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13580-5 PMID: 16174748
  83. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.
    J Natl Cancer Inst. 1998 May 6;90(9):675-84 PMID: 9586664
  84. Colon cancer prognosis prediction by gene expression profiling.
    Oncogene. 2005 Sep 8;24(40):6155-64 PMID: 16091735
  85. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3.
    Nat Genet. 2008 May;40(5):623-30 PMID: 18372905
  86. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.
    Nature. 2004 Dec 9;432(7018):775-9 PMID: 15592418
  87. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    N Engl J Med. 2009 Apr 2;360(14):1408-17 PMID: 19339720
  88. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
    Clin Pharmacol Ther. 1999 May;65(5):576-82 PMID: 10340924
  89. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk.
    Nat Genet. 2008 Jan;40(1):26-8 PMID: 18084292
  90. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    N Engl J Med. 2003 Jul 17;349(3):247-57 PMID: 12867608
  91. Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses.
    Mol Cancer. 2007 Jan 03;6:2 PMID: 17201907
  92. Genetic alterations during colorectal-tumor development.
    N Engl J Med. 1988 Sep 1;319(9):525-32 PMID: 2841597
  93. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment.
    Lancet. 2003 Nov 1;362(9394):1439-44 PMID: 14602436
  94. Glutathione S-transferase polymorphisms: cancer incidence and therapy.
    Oncogene. 2006 Mar 13;25(11):1639-48 PMID: 16550164
  95. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.
    Cancer Treat Rev. 2005 Apr;31(2):90-105 PMID: 15847979
  96. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
    J Mol Diagn. 2006 Nov;8(5):582-8 PMID: 17065427
  97. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
    J Clin Oncol. 2010 Jan 20;28(3):466-74 PMID: 20008640
  98. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Br J Cancer. 2004 Jul 19;91(2):344-54 PMID: 15213713
  99. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients.
    Dis Colon Rectum. 2005 Dec;48(12):2238-48 PMID: 16228831
  100. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.
    Pharmacogenomics. 2007 Nov;8(11):1561-6 PMID: 18034621
  101. Diagnostic and prognostic microRNAs in stage II colon cancer.
    Cancer Res. 2008 Aug 1;68(15):6416-24 PMID: 18676867
  102. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Cancer. 2008 May 1;112(9):1932-40 PMID: 18300238
  103. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.
    JAMA. 2008 Jan 30;299(4):425-36 PMID: 18230780
  104. Systemic treatment of colorectal cancer.
    Gastroenterology. 2008 May;134(5):1296-310 PMID: 18471507
  105. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.
    Nat Genet. 2006 Sep;38(9):1043-8 PMID: 16921376
  106. Network analysis of oncogenic Ras activation in cancer.
    Science. 2007 Oct 19;318(5849):463-7 PMID: 17947584
  107. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.
    Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7 PMID: 11097226
  108. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.
    Cancer Res. 2008 Oct 15;68(20):8541-6 PMID: 18922929
  109. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
    Clin Cancer Res. 2003 May;9(5):1611-5 PMID: 12738713
  110. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.
    Nat Genet. 1995 May;10(1):111-3 PMID: 7647779
  111. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers.
    J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 PMID: 10433618
  112. Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas.
    APMIS. 2004 Jan;112(1):49-56 PMID: 14961975
  113. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil.
    Pharmacology. 2000 Sep;61(3):199-203 PMID: 10971206
  114. Bias as a threat to the validity of cancer molecular-marker research.
    Nat Rev Cancer. 2005 Feb;5(2):142-9 PMID: 15685197
  115. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection.
    Int J Cancer. 2002 Oct 20;101(6):519-25 PMID: 12237891
  116. Capecitabine: have we got the dose right?
    Nat Clin Pract Oncol. 2009 Jan;6(1):17-24 PMID: 18936793
  117. Genomic and epigenetic instability in colorectal cancer pathogenesis.
    Gastroenterology. 2008 Oct;135(4):1079-99 PMID: 18773902
  118. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.
    N Engl J Med. 1978 Aug 31;299(9):448-51 PMID: 683276
  119. SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.
    Br J Cancer. 2002 Sep 9;87(6):630-4 PMID: 12237773
  120. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    N Engl J Med. 2004 Jul 22;351(4):337-45 PMID: 15269313
  121. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.
    Gastroenterology. 2005 Sep;129(3):874-84 PMID: 16143127
  122. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
    J Clin Oncol. 2004 May 1;22(9):1564-71 PMID: 15051756
  123. Predicting fluorouracil toxicity: can we finally do it?
    J Clin Oncol. 2008 May 1;26(13):2080-2 PMID: 18299611
  124. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
    J Clin Oncol. 2005 Mar 20;23(9):1803-10 PMID: 15677699
  125. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer.
    Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8564-9 PMID: 16361538
  126. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.
    Arch Pathol Lab Med. 2000 Jul;124(7):979-94 PMID: 10888773
  127. Metabolism and mechanism of action of 5-fluorouracil.
    Pharmacol Ther. 1990;48(3):381-95 PMID: 1707544
  128. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours.
    Nat Genet. 1996 Nov;14(3):255-7 PMID: 8896552
  129. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.
    Nat Genet. 2006 Jul;38(7):787-93 PMID: 16804544
  130. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    J Clin Oncol. 2007 Aug 10;25(23):3456-61 PMID: 17687149
  131. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
    J Clin Oncol. 2007 Mar 1;25(7):773-80 PMID: 17327601
  132. Alternative genetic pathways in colorectal carcinogenesis.
    Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12122-7 PMID: 9342373
  133. Cadherin-catenin expression in primary colorectal cancer: a survival analysis.
    Br J Cancer. 1999 Jun;80(7):1046-51 PMID: 10362114
  134. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers.
    Cancer Res. 2006 Sep 1;66(17):8462-9468 PMID: 16951157
  135. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer.
    Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 PMID: 18003927
  136. SMAD4 as a prognostic marker in colorectal cancer.
    Clin Cancer Res. 2005 Apr 1;11(7):2606-11 PMID: 15814640
  137. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
    J Natl Cancer Inst. 2005 Jul 6;97(13):981-9 PMID: 15998951
  138. Refining molecular analysis in the pathways of colorectal carcinogenesis.
    Clin Gastroenterol Hepatol. 2005 Nov;3(11):1115-23 PMID: 16271343
  139. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint.
    Cancer Res. 2004 Apr 1;64(7):2502-8 PMID: 15059905
  140. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507 PMID: 17255271
  141. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes.
    Science. 2007 Jun 1;316(5829):1336-41 PMID: 17463249
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2645
Published
2009-07-00
Epub
2009-00-18
Pages
489-99
Language
English
Region
England
NLM ID
101124168
Subset
IM
Corrections
ErratumIn
-
External Links
PubMed source DOI: 10.1038/nrc2645 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2